SG10201903475TA - New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs - Google Patents
New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugsInfo
- Publication number
- SG10201903475TA SG10201903475TA SG10201903475TA SG10201903475TA SG10201903475TA SG 10201903475T A SG10201903475T A SG 10201903475TA SG 10201903475T A SG10201903475T A SG 10201903475TA SG 10201903475T A SG10201903475T A SG 10201903475TA SG 10201903475T A SG10201903475T A SG 10201903475TA
- Authority
- SG
- Singapore
- Prior art keywords
- new substituted
- substituted indazoles
- production
- indazoles
- contain
- Prior art date
Links
- 150000002473 indoazoles Chemical class 0.000 title abstract 7
- 239000003814 drug Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000009273 Endometriosis Diseases 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000005671 spondyloarthropathy Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010051244 Dyschezia Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 208000004483 Dyspareunia Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010013990 dysuria Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001185 psoriatic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
NEW SUBSTITUTED INDAZOLES, METHODS FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAID NEW SUBSTITUTED INDAZOLES, AND USE OF SAID NEW SUBSTITUTED INDAZOLES TO PRODUCE DRUGS The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis- associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis. [No suitable figure]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14195032 | 2014-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201903475TA true SG10201903475TA (en) | 2019-05-30 |
Family
ID=51982455
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201903474PA SG10201903474PA (en) | 2014-11-26 | 2015-11-25 | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs |
| SG10201903475TA SG10201903475TA (en) | 2014-11-26 | 2015-11-25 | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs |
| SG11201704092YA SG11201704092YA (en) | 2014-11-26 | 2015-11-25 | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201903474PA SG10201903474PA (en) | 2014-11-26 | 2015-11-25 | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704092YA SG11201704092YA (en) | 2014-11-26 | 2015-11-25 | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs |
Country Status (42)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016015983A2 (en) | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS, THEIR USES, AND PHARMACEUTICAL COMPOSITION |
| CU24389B1 (en) | 2014-01-13 | 2019-04-04 | Aurigene Discovery Tech Ltd | BICYCLIC HETEROCICLYL COMPOUNDS AS IRAK4 INHIBITORS |
| JO3705B1 (en) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
| WO2016174183A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| EP3195865A1 (en) * | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| CN109153665B (en) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| BR112018072242A2 (en) * | 2016-04-29 | 2019-04-09 | Bayer Pharma Aktiengesellschaft | n- {6- (2-hydroxypropan-2-yl) -2- [2- (methylsulfonyl) ethyl] -2h-indazol-5-yl} -6- (trifluoromethyl) pyridine-2-carboxamide polymorphic form |
| EA035867B1 (en) * | 2016-04-29 | 2020-08-24 | Байер Фарма Акциенгезельшафт | Synthesis of indazoles |
| CU24593B1 (en) * | 2016-04-29 | 2022-05-11 | Bayer Pharma AG | CRYSTALLINE FORMS OF N-[2-(3-HYDROXY-3-METHYLBUTYL)-6-(2-HYDROXYPROPAN-2-IL)-2H-INDAZOL-5-IL]-6-(TRIFLUORMETHYL)- PYRIDINE-2-CARBOXAMIDE |
| RU2743170C2 (en) * | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Substituted indazoles suitable for treating and preventing allergic and/or inflammatory diseases in animals |
| US20190125736A1 (en) * | 2016-06-01 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| TW201811799A (en) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | Pyrazolopyrimidine compounds and uses thereof |
| WO2018060072A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | New substituted benzimidazoles, methods for the production of same, pharmaceutical preparations containing same, and use of same to produce drugs |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| JOP20180011A1 (en) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | PYRROLO[1,2-b] PYRIDAZINE DERIVATIVES |
| KR102633530B1 (en) | 2017-03-31 | 2024-02-02 | 오리진 온콜로지 리미티드 | Compounds and compositions for treating blood disorders |
| US11957931B2 (en) | 2017-04-26 | 2024-04-16 | Yale University | Compositions and methods for treating vitiligo |
| BR112020003292A2 (en) | 2017-08-16 | 2020-08-18 | Vanderbilt University | indazole compounds as allosteric potentiators of mglur4 and their therapeutic uses, as well as pharmaceutical composition and method for the manufacture of medication to enhance the activity of the mglur4 receptor |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators |
| KR20200133747A (en) | 2018-02-20 | 2020-11-30 | 인사이트 코포레이션 | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for treating cancer |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| CN112638430B (en) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | Radiolabeled cannabinoid receptor 2 ligands |
| TWI721483B (en) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | Pyrrolo[1,2-b]pyridazine derivatives |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| CN112513027B (en) * | 2018-08-17 | 2024-03-29 | 浙江海正药业股份有限公司 | Indazole amine derivative, preparation method and medical application thereof |
| CN110835338A (en) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | Imidazopyridine derivative, preparation method and medical application thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| CN111362920B (en) * | 2018-12-25 | 2024-06-07 | 上海美悦生物科技发展有限公司 | Compound as IRAK inhibitor |
| US20220204473A1 (en) * | 2018-12-25 | 2022-06-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Compound as irak inhibitor |
| CN111499612B (en) * | 2019-01-30 | 2022-12-30 | 上海美悦生物科技发展有限公司 | Compound as IRAK inhibitor and preparation method and application thereof |
| CN111560012B (en) * | 2019-02-14 | 2023-06-23 | 上海美悦生物科技发展有限公司 | Compound as IRAK inhibitor |
| CN111793064B (en) * | 2019-04-02 | 2023-06-23 | 上海美悦生物科技发展有限公司 | Compound serving as IRAK inhibitor as well as preparation method and application thereof |
| WO2020259626A1 (en) * | 2019-06-26 | 2020-12-30 | 南京明德新药研发有限公司 | Imidazopyridine compound as irak4 inhibitor |
| KR20220042132A (en) * | 2019-06-27 | 2022-04-04 | 바이오젠 엠에이 인코포레이티드 | 2H-imidazole derivatives and their use in the treatment of diseases |
| JP2022540200A (en) | 2019-07-11 | 2022-09-14 | エスケイプ・バイオ・インコーポレイテッド | Indazole and Azaindazole as LRRK2 Inhibitors |
| KR20220059480A (en) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | HPK1 inhibitor in solid form |
| LT4015513T (en) * | 2019-09-24 | 2023-12-11 | Shanghai Meiyue Biotech Development Co., Ltd. | Irak inhibitor and preparation method therefor and use thereof |
| CN111072634B (en) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-substituted-3-substituted-5-substituted amide-1H-indole compound and preparation method and application thereof |
| CN113521079A (en) * | 2020-04-20 | 2021-10-22 | 上海领泰生物医药科技有限公司 | Use of IRAK4 inhibitors for the treatment of ALI/ARDS |
| US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
| CN113278017B (en) * | 2021-05-27 | 2023-03-28 | 上海应用技术大学 | Substituted indazoles, preparation method, application and composition containing same |
| CN113402499B (en) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | Sulfimide substituted indazole IRAK4 kinase inhibitor, preparation method and application |
| EP4366834A1 (en) * | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
| WO2023098857A1 (en) * | 2021-12-03 | 2023-06-08 | 武汉人福创新药物研发中心有限公司 | Irak4 inhibitor and use thereof |
| WO2024108010A1 (en) * | 2022-11-17 | 2024-05-23 | Bayer Animal Health Gmbh | Methods and compositions for control of pain and inflammation |
| CN116120283A (en) * | 2022-12-13 | 2023-05-16 | 药康众拓(北京)医药科技有限公司 | Deuterated picolinamide IRAK-4 inhibitor drug and application thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246606B1 (en) | 2002-07-23 | 2007-06-01 | Izar Construcciones Navales S.A. | SEMI-SUBMERSIBLE SELF-PROMISED UNIT FOR TRANSPORTATION AND LIVING OF LIVING FISH. |
| RU2005105683A (en) * | 2002-07-31 | 2006-01-20 | Шеринг Акциенгезельшафт (De) | POSSESSING INHIBITING ACTION ON VEGFR-2 AND VEGFR-3 ANTHRANILAMIDOPYRIDINES |
| WO2004113281A1 (en) | 2003-06-25 | 2004-12-29 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them |
| WO2005082866A2 (en) | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| CA2591332A1 (en) | 2004-12-08 | 2006-06-15 | Warner-Lambert Company Llc | Methylene inhibitors of matrix metalloproteinase |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| GT200600411A (en) * | 2005-09-13 | 2007-05-21 | Novartis Ag | COMBINATIONS THAT INCLUDE AN INHIBITOR OF THE RECEIVER OF THE VASCULAR ENDOTELIAL GROWTH FACTOR |
| GB0518671D0 (en) * | 2005-09-13 | 2005-10-19 | Novartis Ag | Organic compounds |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| WO2007091107A1 (en) | 2006-02-10 | 2007-08-16 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| TWI435863B (en) | 2006-03-20 | 2014-05-01 | Nihon Nohyaku Co Ltd | N-2-(hetero) arylethylcarboxamide derivative and pest controlling |
| EP2045253A4 (en) | 2006-06-29 | 2013-01-23 | Nissan Chemical Ind Ltd | alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT |
| WO2008030584A2 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Indazole derivatives as modulators of interleukin- 1 receptor-associated kinase |
| FR2917735B1 (en) | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | NEW SUBSTITUTED INDAZOLES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2012061926A1 (en) | 2010-11-08 | 2012-05-18 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| CA2822166C (en) * | 2010-12-20 | 2019-10-29 | Merck Serono S.A. | Indazolyl triazole derivatives as irak inhibitors |
| US8748432B2 (en) | 2011-02-10 | 2014-06-10 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| ES2591129T3 (en) | 2012-05-21 | 2016-11-25 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
| JP2015002717A (en) | 2013-06-21 | 2015-01-08 | 住友ベークライト株式会社 | Container with lid |
| TWI667233B (en) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments |
| BR112016015983A2 (en) | 2014-01-10 | 2017-08-08 | Aurigene Discovery Tech Ltd | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS, THEIR USES, AND PHARMACEUTICAL COMPOSITION |
| MX2016017147A (en) | 2014-06-20 | 2017-06-07 | Aurigene Discovery Tech Ltd | Substituted indazole compounds as irak4 inhibitors. |
| JO3705B1 (en) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| BR112018000624A2 (en) | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | indazole and azaindazole compounds as irak-4 inhibitors |
| CN109153665B (en) | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| CU24593B1 (en) | 2016-04-29 | 2022-05-11 | Bayer Pharma AG | CRYSTALLINE FORMS OF N-[2-(3-HYDROXY-3-METHYLBUTYL)-6-(2-HYDROXYPROPAN-2-IL)-2H-INDAZOL-5-IL]-6-(TRIFLUORMETHYL)- PYRIDINE-2-CARBOXAMIDE |
| BR112018072242A2 (en) | 2016-04-29 | 2019-04-09 | Bayer Pharma Aktiengesellschaft | n- {6- (2-hydroxypropan-2-yl) -2- [2- (methylsulfonyl) ethyl] -2h-indazol-5-yl} -6- (trifluoromethyl) pyridine-2-carboxamide polymorphic form |
| RU2743170C2 (en) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Substituted indazoles suitable for treating and preventing allergic and/or inflammatory diseases in animals |
| US20190125736A1 (en) | 2016-06-01 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
-
2015
- 2015-11-23 JO JOP/2015/0287A patent/JO3705B1/en active
- 2015-11-25 SG SG10201903474PA patent/SG10201903474PA/en unknown
- 2015-11-25 WO PCT/EP2015/077596 patent/WO2016083433A1/en active Application Filing
- 2015-11-25 US US15/529,996 patent/US10308634B2/en active Active
- 2015-11-25 AU AU2015352603A patent/AU2015352603B2/en active Active
- 2015-11-25 DK DK15800828.4T patent/DK3224254T3/en active
- 2015-11-25 CN CN201580073989.1A patent/CN107406416B/en active Active
- 2015-11-25 EP EP23189515.2A patent/EP4260909A3/en active Pending
- 2015-11-25 PL PL15800828T patent/PL3224254T3/en unknown
- 2015-11-25 ES ES15800828T patent/ES2796285T3/en active Active
- 2015-11-25 NZ NZ732126A patent/NZ732126A/en unknown
- 2015-11-25 UA UAA201706382A patent/UA120948C2/en unknown
- 2015-11-25 TN TN2017000226A patent/TN2017000226A1/en unknown
- 2015-11-25 MX MX2017006910A patent/MX2017006910A/en unknown
- 2015-11-25 DK DK19191936.4T patent/DK3674298T3/en active
- 2015-11-25 PE PE2017000922A patent/PE20171376A1/en unknown
- 2015-11-25 HR HRP20240414TT patent/HRP20240414T1/en unknown
- 2015-11-25 JP JP2017528139A patent/JP6496823B2/en active Active
- 2015-11-25 MA MA41011A patent/MA41011B1/en unknown
- 2015-11-25 BR BR122021002613-0A patent/BR122021002613B1/en active IP Right Grant
- 2015-11-25 CR CR20170220A patent/CR20170220A/en unknown
- 2015-11-25 EP EP19191936.4A patent/EP3674298B9/en active Active
- 2015-11-25 CA CA2968614A patent/CA2968614C/en active Active
- 2015-11-25 SI SI201531182T patent/SI3224254T1/en unknown
- 2015-11-25 MX MX2020010623A patent/MX2020010623A/en unknown
- 2015-11-25 SG SG10201903475TA patent/SG10201903475TA/en unknown
- 2015-11-25 EP EP15800828.4A patent/EP3224254B1/en active Active
- 2015-11-25 ME MEP-2020-115A patent/ME03745B/en unknown
- 2015-11-25 LT LTEP19191936.4T patent/LT3674298T/en unknown
- 2015-11-25 CU CU2017000073A patent/CU24448B1/en unknown
- 2015-11-25 BR BR112017011005-9A patent/BR112017011005B1/en active IP Right Grant
- 2015-11-25 RS RS20200564A patent/RS60284B1/en unknown
- 2015-11-25 SG SG11201704092YA patent/SG11201704092YA/en unknown
- 2015-11-25 UA UAA201909772A patent/UA123813C2/en unknown
- 2015-11-25 HU HUE15800828A patent/HUE049341T2/en unknown
- 2015-11-25 PT PT191919364T patent/PT3674298T/en unknown
- 2015-11-25 RS RS20240330A patent/RS65327B1/en unknown
- 2015-11-25 SI SI201532005T patent/SI3674298T1/en unknown
- 2015-11-25 CN CN201910670725.4A patent/CN110305109B/en active Active
- 2015-11-25 KR KR1020177017079A patent/KR102083857B1/en active IP Right Grant
- 2015-11-25 PT PT158008284T patent/PT3224254T/en unknown
- 2015-11-25 LT LTEP15800828.4T patent/LT3224254T/en unknown
- 2015-11-25 EA EA201791137A patent/EA032509B1/en not_active IP Right Cessation
- 2015-11-25 FI FIEP19191936.4T patent/FI3674298T3/en active
- 2015-11-26 UY UY0001036411A patent/UY36411A/en active IP Right Grant
- 2015-11-26 TW TW108137338A patent/TWI717061B/en active
- 2015-11-26 AR ARP150103876A patent/AR102827A1/en active IP Right Grant
- 2015-11-26 TW TW104139563A patent/TWI689502B/en active
-
2017
- 2017-05-09 IL IL25218517A patent/IL252185B/en active IP Right Grant
- 2017-05-25 EC ECIEPI201732530A patent/ECSP17032530A/en unknown
- 2017-05-25 PH PH12017500972A patent/PH12017500972A1/en unknown
- 2017-05-26 DO DO2017000127A patent/DOP2017000127A/en unknown
- 2017-05-26 NI NI201700063A patent/NI201700063A/en unknown
- 2017-05-26 CL CL2017001364A patent/CL2017001364A1/en unknown
- 2017-06-26 CO CONC2017/0005374A patent/CO2017005374A2/en unknown
-
2019
- 2019-04-05 US US16/377,025 patent/US10793545B2/en active Active
- 2019-06-20 IL IL267537A patent/IL267537B/en active IP Right Grant
- 2019-09-19 IL IL269444A patent/IL269444B/en active IP Right Grant
-
2020
- 2020-02-11 AU AU2020200979A patent/AU2020200979B2/en active Active
- 2020-06-05 CY CY20201100506T patent/CY1123815T1/en unknown
- 2020-06-19 HR HRP20200974TT patent/HRP20200974T1/en unknown
- 2020-09-01 US US17/009,553 patent/US20210053941A1/en not_active Abandoned
-
2022
- 2022-07-20 US US17/869,674 patent/US12006304B2/en active Active
- 2022-07-20 US US17/869,673 patent/US12006303B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201903474PA (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2019012081A (en) | Human fibroblast growth factor 21 (hfgf21) fusion protein, preparation method therefor, and use thereof. | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12021551189A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
| SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
| MX2017006483A (en) | Aminopyrazine compounds with a2a antagonist properties. | |
| MX355065B (en) | Laquinimod for reducing thalamic damage in multiple sclerosis. | |
| WO2015165413A8 (en) | New stable antibody-drug conjugate, preparation method therefor, and use thereof | |
| JO3784B1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| PH12019502576A1 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| PH12016500814A1 (en) | Heteroaryl butanoic acid derivatives | |
| MX2019006495A (en) | Treatment of neurological diseases. | |
| MX2017003216A (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients. | |
| PH12018502278A1 (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| MX2018005226A (en) | Anti-factor d antibody formulations. | |
| PL3085383T3 (en) | A pharmaceutical composition comprising erythropoietin and ceftriaxone and a use thereof in the manufacture of a medicament for the treatment of parkinson's disease dementia | |
| WO2014031034A8 (en) | Pharmaceutical compositions containing ipidacrine and use thereof to treat potency disorders and other sexual activity disorders | |
| MD20150017A2 (en) | Use of Polybiolin drug in patients with liver cirrhosis | |
| PL409386A1 (en) | Peptide preparations to be used as a pharmaceutical or food additive in prevention and treatment of neurodegenerative diseases |